TOXICITY OF LEAD IN CHILDREN--CLINICAL TRIAL

随机儿童的平均血铅为26 mg/dl：琥珀酰亚胺产生了缓慢反弹的突然下降，琥珀酰亚胺组儿童的血铅保持低于安慰剂组儿童6个月。 在服用活性药物的儿童中，因创伤而住院的情况更常见，但创伤事件中没有可辨别的模式。 由于铅污染，TLC不得不召回其维生素和矿物质补充剂，但在分发受污染补充剂的3个月左右时间里，没有发现对铅水平的任何影响。所有儿童均已完成治疗阶段。安慰剂治疗的儿童血铅水平逐渐下降。接受琥珀酰亚胺治疗的儿童血铅突然下降，随后又反弹。在开始治疗后的六个月内，接受琥珀酰亚胺治疗的儿童的平均血铅比接受安慰剂治疗的儿童低4.5 mg/dL。 几乎没有与救援相关的副作用，但在接受救援治疗的儿童中出现了意外的过度创伤。总之，琥珀酰胆碱降低血铅，副作用少。三年的发展跟进工作将于2000年3月左右完成。

Mean blood lead in the randomized children is 26 mg/dl: succimer produced an abrupt drop with slow rebound, and blood lead in children given succimer remain below those of the children given placebo for 6 months. Hospitalization for trauma is more frequent in the children on active drug, but there is no discernable pattern within the traumatic events. TLC had to recall its vitamin and mineral supplement because of lead contamination, but did not find any effect on lead levels from the 3 months or so during which the contaminated supplements were dispensed. All children have completed the treatment phase. Placebo-treated children had a gradual decrease in blood lead. Succimer-treated children had an abrupt drop in blood lead, followed by rebound. The mean blood lead of the succimer-treated children over the six months following initiation of treatment was 4.5 mg/dL lower than that of placebo-treated children. There were few succimer-related side effects, but there was an unanticipated excess of trauma in the succimer-treated children. In summary, succimer lowers blood lead with few side effects. Three years of developmental follow up will be completed in about March 2000.